Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | KDM6B | O15054 | 2/20 | 0.55 |
| ▸ | KDM5C | P41229 | 2/20 | 0.55 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.55 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.55 |
| ▸ | KDM3A | Q9Y4C1 | 2/20 | 0.55 |
| ▸ | JMJD6 | Q6NYC1 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30016171 | 0.97 | KDM4E (0.55) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL16445734 | 0.94 | KDM4E (0.58) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL30755291 | 0.87 | KDM4E (0.51) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL27370534 | 0.87 | KDM4E (0.51) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL31320054 | 0.86 | KDM4E (0.50) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL26087368 | 0.81 | KDM4C (0.50) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL30379389 | 0.81 | KDM4C (0.50) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL25702318 | 0.78 | JMJD6 (0.54) | KDM4EKDM5CKDM4CJMJD6PROKR1 | |
| SCHEMBL30016583 | 0.78 | JMJD6 (0.54) | KDM4EKDM5CKDM4CJMJD6PROKR1 | |
| SCHEMBL16055561 | 0.78 | KMO (0.53) | KDM4EKDM6BKDM5CKDM4CKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023070053-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023070053-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20190152979-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2019-05-23 | — | — | US | disclosed |
| US-10221179-B2 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | DOMAIN THERAPEUTICS (FR) | 2019-03-05 | — | — | US | disclosed |
| US-20170305913-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2017-10-26 | — | — | US | disclosed |
| EP-3197897-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP IIMETABOTROPIC GLUTAMATE RECEPTORS | Domain Therapeutics (FR) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046404-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP IIMETABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221179-B2 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | GRM1, GRM2, GRIN1 | KDM4E 2164/4885KDM6B 2638/4885KDM5C 1939/4885 |
| US-20170305913-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM1, GRM2, GRIN1 | KDM4E 2164/4885KDM6B 2638/4885KDM5C 1939/4885 |
| US-20190152979-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM1, GRM2, GRIN1 | KDM4E 2238/4885KDM6B 2611/4885KDM5C 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.